Silodosin
Active ingredient: Silodosin
In short: Silodosin, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) . Silodosin capsules are not indicated for the treatment of hypertension.
What is Silodosin used for?
Silodosin, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH)
.
Silodosin capsules are not indicated for the treatment of hypertension.
Silodosin dosage
The recommended dose is 8 mg orally once daily with a meal.
Patients who have difficulty swallowing pills and capsules may carefully open the silodosin capsule and sprinkle the powder inside on a tablespoonful of applesauce. The applesauce should be swallowed immediately (within 5 minutes) without chewing and followed with an 8 oz glass of cool water to ensure complete swallowing of the powder. The applesauce used should not be hot, and it should be soft enough to be swallowed without chewing. Any powder/applesauce mixture should be used immediately (within 5 minutes) and not stored for future use. Subdividing the contents of a silodosin capsule is not recommended
.
Renal impairment: Silodosin capsules are contraindicated in patients with severe renal impairment (CCr < 30 mL/min). In patients with moderate renal impairment (CCr 30 to 50 mL/min), the dose should be reduced to 4 mg once daily taken with a meal. No dosage adjustment is needed in patients with mild renal impairment (CCr 50 to 80 mL/min)
[see
CONTRAINDICATIONS (4),
WARNINGS AND PRECAUTIONS (5.2),
USE IN SPECIFIC POPULATIONS (8.6)and
CLINICAL PHARMACOLOGY (12.3)].
Hepatic impairment: Silodosin capsules have not been studied in patients with severe hepatic impairment (Child-Pugh score ≥ 10) and is therefore contraindicated in these patients. No dosage adjustment is needed in patients with mild or moderate hepatic impairment
[see
CONTRAINDICATIONS (4),
WARNINGS AND PRECAUTIONS (5.3),
USE IN SPECIFIC POPULATIONS (8.7)and
CLINICAL PHARMACOLOGY (12.3)].
How to take Silodosin — instructions & advice from the label
Advise patients to take silodosin once daily with a meal
.
Advise patients about the possible occurrence of symptoms related to postural hypotension (such as dizziness), and should be cautioned about driving, operating machinery, or performing hazardous tasks until they know how silodosin will affect them. This is especially important for those with low blood pressure or who are taking antihypertensive medications
.
Counsel patients on that the most common side effect seen with silodosin is an orgasm with reduced or no semen. This side effect does not pose a safety concern and is reversible with discontinuation of the product
.
Counsel patients to tell their ophthalmologist about the use of silodosin before cataract surgery or other procedures involving the eyes, even if the patient is no longer taking silodosin
.
Distributed by:
Aurobindo Pharma USA, Inc.
279 Princeton-Hightstown Road
East Windsor, NJ 08520
Manufactured by:
Aurobindo Pharma Limited
Hyderabad-500 032, India
Revised: 07/2021
Warnings & precautions
Do not take this medicine if: Severe renal impairment (CCr < 30 mL/min)
Severe hepatic impairment (Child-Pugh score ≥ 10)
Concomitant administration with strong Cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ketoconazole, clarithromycin, itraconazole, ritonavir)
Patients with a history of hypersensitivity to silodosin or any of the ingredients of silodosin capsules
Postural hypotension, with or without symptoms (e.g., dizziness) may develop when beginning silodosin treatment. As with other alpha-blockers, there is potential for syncope. Patients should be cautioned about driving, operating machinery, or performing hazardous tasks when initiating therapy
[see
ADVERSE REACTIONS (6),
USE IN SPECIFIC POPULATIONS (8.5),
CLINICAL PHARMACOLOGY (12.2), and
PATIENT COUNSELING INFORMATION (17)].
In a clinical pharmacology study, plasma concentrations (AUC and C
max) of silodosin were approximately three times higher in subjects with moderate renal impairment compared with subjects with normal renal function, while half-lives of silodosin doubled in duration. The dose of silodosin should be reduced to 4 mg in patients with moderate renal impairment. Exercise caution and monitor such patients for adverse events
.
Silodosin is contraindicated in patients with severe renal impairment
.
Silodosin has not been tested in patients with severe hepatic impairment, and therefore, should not be prescribed to such patients
[see
CONTRAINDICATIONS (4),
USE IN SPECIFIC POPULATIONS (8.7)and
CLINICAL PHARMACOLOGY (12.3)].
In a drug interaction study, co-administration of a single 8 mg dose of silodosin with 400 mg ketoconazole, a strong CYP3A4 inhibitor, caused a 3.8-fold increase in maximum plasma silodosin concentrations and 3.2-fold increase in silodosin exposure (i.e., AUC). …
Silodosin side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
In U.S. clinical trials, 897 patients with BPH were exposed to 8 mg silodosin daily. This includes 486 patients exposed for 6 months and 168 patients exposed for 1 year. The population was 44 to 87 years of age, and predominantly Caucasian. Of these patients, 42.8% were 65 years of age or older and 10.7% were 75 years of age or older.
In double-blind, placebo controlled, 12-week clinical trials, 466 patients were administered silodosin and 457 patients were administered placebo. At least one treatment-emergent adverse reaction was reported by 55.2% of silodosin treated patients (36.8% for placebo treated). The majority (72.1%) of adverse reactions for the silodosin treated patients (59.8% for placebo treated) were qualified by the investigator as mild. A total of 6.4% of silodosin treated patients (2.2% for placebo treated) discontinued therapy due to an adverse reaction (treatment-emergent), the most common reaction being retrograde ejaculation (2.8%) for silodosin treated patients. Retrograde ejaculation is reversible upon discontinuation of treatment. …
Drug interactions
In a clinical metabolic inhibition study, a 3.8-fold increase in silodosin maximum plasma concentrations and 3.2-fold increase in silodosin exposure were observed with concurrent administration of a strong CYP3A4 inhibitor, 400 mg ketoconazole. Use of strong CYP3A4 inhibitors such as itraconazole or ritonavir may cause plasma concentrations of silodosin to increase. Concomitant administration of strong CYP3A4 inhibitors and silodosin is contraindicated
[see
CONTRAINDICATIONS (4),
WARNINGS AND PRECAUTIONS (5.4)and
CLINICAL PHARMACOLOGY (12.3)].
The effect of moderate CYP3A4 inhibitors on the pharmacokinetics of silodosin has not been evaluated. Concomitant administration with moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil) may increase concentration of silodosin. Exercise caution and monitor patients for adverse events when co-administering silodosin with moderate CYP3A4 inhibitors.
In vitrostudies indicated that silodosin is a P-gp substrate. Ketoconazole, a CYP3A4 inhibitor that also inhibits P-gp, caused significant increase in exposure to silodosin. Inhibition of P-gp may lead to increased silodosin concentration. Silodosin is therefore not recommended in patients taking strong P-gp inhibitors such as cyclosporine
. …
About this medicine
Silodosin, a selective antagonist of alpha-1 adrenoreceptors. The chemical name of silodosin is 1-(3-Hydroxypropyl)-5-[(2
R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1
H-indole-7-carboxamide and the molecular formula is C
25H
32F
3N
3O
4with a molecular weight of 495.53. The structural formula of silodosin is:
Silodosin is a white to pale yellowish white powder that melts at approximately 105 to 109°C. It is freely soluble in ethanol, methanol, N,N-dimethylformamide and practically insoluble in water and 1-Octanol.
Each silodosin 8 mg capsule and 4 mg capsule for oral administration contains 8 mg silodosin and 4 mg silodosin respectively and the following inactive ingredients: hydrogenated vegetable oil, mannitol, pregelatinized starch (maize) and sodium lauryl sulfate. In addition, the empty hard gelatin capsules contain gelatin and titanium dioxide. The capsules are imprinted with edible ink containing black iron oxide, potassium hydroxide, propylene glycol, shellac and strong ammonia solution. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 94bca72c-c74a-4181-8b6a-a0a2f654a0a7. Read the full official label on DailyMed.
Related medicines
Amlodipine Lisinopril Metoprolol Hydrochlorothiazide Tamsulosin Carvedilol Potassium Chloride Spironolactone